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Numerous studies have shown that the bone marrow
(BM) niche plays a key role in mouse hematopoietic
stem cell (HSC) function and involves contributions
from a broad array of cell types. However, the
composition and role of the human BM HSC niche
have not been investigated. Here, using human
bone biopsy specimens, we provide evidence of
HSC propensity to localize to endosteal regions of
the trabecular bone area (TBA). Through functional
xenograft transplantation, we found that human
HSCs localizing to the TBA have superior regenera-
tive and self-renewal capacity and are molecularly
distinct from those localizing to the long bone area
(LBA). In addition, osteoblasts in the TBA possess
unique characteristics and express a key network
of factors that regulate TBA- versus LBA-localized
human HSCs in vivo. Our study reveals that BM
localization and architecture play a critical role in
defining the functional and molecular properties of
human HSCs.
INTRODUCTION
Human hematopoietic stem cell (HSC) transplants have been
successfully performed clinically for over 40 years, but their effi-
cacy can be limited due to the difficulty in obtaining sufficient
numbers of donor HSCs required to reconstitute the hematopoi-
etic system (Hodby and Pamphilon, 2011). Based on the notion
that HSCs operate in a cell-autonomous fashion, isolation and
transplantation of greater numbers of human HSCs is thought
to be a plausible solution. This approach, however, is con-
strained both by the inability to expand and maintain these cells
ex vivo (Kelly et al., 2010) and by the difficulty in obtaining larger
numbers of donor HSCs (Schoemans et al., 2006). This is furtherCcomplicated by limitations in purifying HSCs due to the signifi-
cant phenotypic (Doulatov et al., 2012) and functional heteroge-
neity in cell populations enriched for hematopoietic regenerative
capacity (Schoemans et al., 2006; Hope and Bhatia, 2011).
Currently, putative human HSCs have been identified and en-
riched based upon their ability to reconstitute long-term multili-
neage hematopoiesis in immunodeficient mice (Larochelle
et al., 1996; Bhatia et al., 1997; Conneally et al., 1997). However,
more recent lentiviral-based genomic integration studies have
allowed clonal tracking analyses that reveal significant functional
heterogeneity, at the single-cell level, of human blood cells
capable of in vivo hematopoietic reconstitution (Mazurier et al.,
2004; McKenzie et al., 2006). These elegant studies underscore
the premise that the ultimate control of HSC cell fate decisions is
not cell-autonomously governed but instead is tightly organized
in combination with instructive non-cell-autonomous effects
provided by the bone marrow (BM) microenvironment where
HSCs ultimately reside and are experimentally detected. As
such, alternative strategies to increase the regenerative capacity
of a finite number of available HSCs may be possible by modu-
lating the non-cell-autonomous nature of HSC function by tar-
geting the BM microenvironment in vivo (Trowbridge et al.,
2006; Adams et al., 2007).
The concept of the ‘‘HSC niche’’ was proposed to capture
and define the molecular pathways that underlie the interactions
between individual HSCs and their BM microenvironment that
allow hematopoiesis to be sustained (Dexter et al., 1977; Scho-
field, 1978; Scadden, 2006; Morrison and Spradling, 2008). In
the mouse, HSCs reside in a variety of in vivo niches that include
the endosteal surface lined primarily by osteoblasts (OBs) (Calvi
et al., 2003; Zhang et al., 2003), vascular cells (Butler et al.,
2010; Kiel et al., 2005), osteoprogenitors, stromal cells, osteo-
clasts, adipocytes, and neurons (Katayama et al., 2006; Kollet
et al., 2006; Sugiyama et al., 2006; Naveiras et al., 2009; Me´n-
dez-Ferrer et al., 2010). Unfortunately, such precise character-
ization in the human BM is limited by our lack of insights into
the cellular nature of BM niche cells and interior regions of the
bone that support bona fide human HSCs. This is further hin-
dered by the absence of model systems that validate humanell Stem Cell 13, 175–189, August 1, 2013 ª2013 Elsevier Inc. 175
Figure 1. Structural and Cellular Bone Marrow Similarities between Human Biopsy Specimens and Human HSC-Mouse Xenograft
(A) Representative bone marrow (BM) trephine bone biopsy specimen section from a human donor. Scale bar = 300 mm. Detection of human CD45+ was per-
formed at higher magnification (indicated by the dashed box).
(B–D) Primitive hematopoietic cells (HSPCs) were discriminated by tracking the CD45+CD34+ double-stained cells (white arrowheads). (B) Human CD34+ cells
(white arrows) were associated with the endosteum (OPN) (yellow arrowheads), (C) attached to the sinusoidal vascular cells (CD31), or (D) located between
endosteum and blood vessels. Scale bar, 50 mm.
(legend continued on next page)
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during transplantation in human patients or mouse-to-mouse
transplantation.
Here, we characterize indigenous location of human hemato-
poietic stem-progenitor cells (HSPCs) within human BM biopsy
specimens. In vivo human-mouse xenografts provided a surro-
gate to functionally validate observations from human bone
and revealed unique human HSC subsets located exclusively
in the trabecular bone area (TBA) that possess superior regener-
ative capacity. This subclass of TBA-HSCs is sustained by key
network of factors, including those required for Notch activity,
and by TBA-residing OBs. Our study provides human-based
evidence for the non-cell-autonomous nature of HSC behavior
in vivo, thereby forming the basis for targeted modulatory strate-
gies to augment HSC regenerative capacity in the clinic and
defines human HSCs through an extended phenotype beyond
cell-surface markers that should include HSC location within
the BM space.
RESULTS
Human Bone Biopsy Specimens Reveal an HSPC BM
Location that Is Recapitulated in Human-Mouse
Xenografts
Human BM trephine biopsy specimens were obtained from indi-
vidual donors as part of their diagnostic procedures, of which
five samples deemed normal and disease-free were used for
direct in situ analysis by high-resolution fluorescent scanning
(Sachlos et al., 2012) to determine the crude proximity of HSPCs
to cellular and structural spaces in human bone (Figure S1A
available online). Using optimized conditions for human tissue
preparation and sectioning (Jiang et al., 2005; Naresh et al.,
2006), hematopoietic cells were identified using a human-
specific pan-leukocyte marker CD45 (huCD45) together with
the endosteal marker human osteopontin (huOPN) to provide a
general macroscopic analysis of hematopoietic cell location
throughout the BM samples (Figure 1A). The degree of cellularity
and overall frequency of total HSPCs were congruent across all
samples (Figure S1E). Individual sections were further analyzed
in detail for location of human HSPCsmarked by double-positive
CD45 and CD34 (huCD34) together with huOPN (Figure 1B)
and vascular cells using the human pan-endothelial marker
PECAM-1 (huCD31) (Figure 1C) alone and in combination (Fig-
ure 1D). These results provide evidence that human HSPCs
physically reside in both vascular and endosteal niche locations.
Given the limitation of analyses resulting from a restricted
selection of sections attainable from human bone biopsy speci-
mens, we extended these observations from human bone
(Figures 1A–1D) to recipient immunodeficient mice trans-
planted with human cells to allow a multilineage human hemato-
poietic reconstitution from putative human HSCs operationally
defined as severe combined immunodeficient repopulating cells(E) Representative BM section of mouse xenografted femur revealing correlation
(F–H) Engrafted human CD45+CD34+ HSPCs were also associated with (F) en
(scale bar, 50 mm).
(I) Graphical summary of CD34+ HSPC distribution within the BM shows noticeable
mice; n0 = 10 sections).
See also Figure S1.
C(SRCs) (Guezguez and Bhatia, 2008; Shultz et al., 2007). Spatial
organization of individual human hematopoietic cells (huCD45+
huCD34+) engrafting recipient mouse BM were identified in situ
(Figures 1E–1H; Figures S1B and S1C). Quantitative analysis
using high-resolution imaging was used to capture crude prox-
imity of HSPCs to recipient endosteal regions using mouse
osteopontin (mOPN) (Figures 1F and 1H) or vascular cells using
mouse PECAM-1-mCD31 (Figures 1G and 1H). These data from
human-mouse xenografts were quantitatively compared to
human bone biopsy specimens. Human xenografted HSPCs
reside within both endosteal and vascular BM niches of recipient
mice (Figures 1G and 1H), similar to indigenous HSPCs in human
bone (Figures 1A–1D). Despite the unbiased cellular BM niche
environments available to intravenously transplanted human
hematopoietic cells, HSPCs preferentially resided in the endos-
teal regions of reconstituted mice, similar to indigenous human
HSPCs identified from in situ analysis of human donor bone
biopsies (85% versus 15%; Figure 1I; Figures S1D and S1E).
These initial observations indicate that BM regions harboring
HSPCs in humans can be modeled in human-mouse BM
xenografts.
Indigenous Human HSCs Are Enriched in
Trabecular Bone
Previous studies in the mouse hematopoietic system have sug-
gested that aside from individual cellular niches or microstruc-
tures, aspects of the macrostructure of the BM anatomy can
be subdivided between the middle/central portion of the BM
cavity (long bone area [LBA]) and cancellous cortical bone
ends (TBA) (Calvi et al., 2003; Colvin et al., 2010; Dominici
et al., 2009; Lo Celso et al., 2009; Xie et al., 2009; Zhang et al.,
2003). Using high-resolution scanning and montage imaging
approaches for relative position determination (Figures 2A and
2B), we quantitated the frequency of putative human HSCs
(CD45+CD34+CD38; Figure 2C) and HPCs (CD45+CD34+
CD38+; Figure 2C) over the complete topology of human trephine
biopsy specimens that contained both subcortical iliac crest
core sections enriched in trabecular bone (TBA-like; Figure 2B)
and deeper central core sections with sparse trabecular struc-
tures (LBA-like; Figure 2B). Primitive HSCs were preferentially
located at higher frequency in all cortical regions (TBA-like) in
human bone (Figure 2D), while HPCs were dispersed evenly
between both anatomical regions (Figure 2E). Importantly, these
human HSC and HPC positional hallmarks were conserved
in situ within the BM cavity of humans and mice (Figure 2F). A
similar approach of hematopoietic stem cell compartment char-
acterization of human biopsy specimens was performed using
extensive HSC and HPC immunophenotyping by flow cytometry
on both de novo isolated TBA and LBA areas (Figure 2G). Both
defined regions were anatomically assessed by histology and
immunohistochemistry (Figure 2H). We observed enrichment of
bulk HSCs (phenotypically defined LinCD45RACD34+CD38;with (A) human BM section. Scale bar, 500 mm.
dosteum surface (OPN), (G) vascular cells (vessels) (CD31), or (H) between
similarities between human andmouse (N = 5 patients, n = 10 sections; N0 = 10
ell Stem Cell 13, 175–189, August 1, 2013 ª2013 Elsevier Inc. 177
Figure 2. Human HSCs Are Anatomically Enriched in the Trabecular Bone
(A) Experimental design outlining the different procedures of BM section imaging and postprocessing analysis.
(B) Representative montage of a human BM biopsy section illustrating the delineation between the sparse and enriched cortical area (red asterisks). Scale
bar, 500 mm.
(legend continued on next page)
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CD49f+ HSC primitive subset cells (phenotypically defined
LinCD34+CD38CD45RACD49f+; Notta et al., 2011; Fig-
ure S2) compared to LBA-HSCs (Figures 2I and 2K). Interest-
ingly, HPC subsets were found at similar levels in both the LBA
and TBA (Figures 2I and 2L). Functional in vitro hematopoietic
potential measurement of these distinct populations revealed
superior hematopoietic progenitor (colony-forming units [CFU])
content from the TBA compared to LBA (Figure 2M; Figure S2E).
Collectively, these data represent in situ and de novo character-
ization of the human HSC and HPC compartments in the BM
space of humans.
Functional Properties of Human HSCs Are Conserved in
Human-Mouse Xenografted Bone
Given the observed enrichment of indigenous human HSCs in
the TBA of human bone (Figure 2), we explored the functional
relevance of the specific macroniche locations of human HSC
using in vivo transplantation studies. As illustrated in Figure 3A,
human cells enriched for putative HSCs capable of hemato-
poietic reconstitution were transplanted into immunodeficient
mice to establish multilineage hematopoiesis (i.e., SRCs). Long
bones of primary recipient mice were anatomically subdivided
into TBA and LBA (Figure 3B) using histological guided surgical
separations, where LBA and TBA are defined by the margins of
the epiphyses, metaphyses, and diaphyses (Figure 3B). Analysis
of mouse xenografts demonstrated that total human CD45+ SRC
engraftment was on average 2.5-fold greater in the TBA versus
the LBA (Figures 3C and 3D). This difference was further
enhanced for the engrafted human CD34+CD38 cells enriched
for HSCs, which were 4-fold more prevalent in the TBA than LBA
(Figure 3E). In contrast, primitive CD34+CD38+ cells representing
HPCs were equally distributed in the TBA and LBA (Figure 3F).
Importantly and similarly to native human bone, within themouse
TBA, a larger proportion of the TBA-SRCs were enriched for the
early primitive CD49f+ HSC subsets as compared to the SRC in
the LBA region (Figure 3G). A corresponding reduction of more
differentiated CD49f HSC subsets was observed within TBA-
SRCs in contrast to LBA-SRCs (Figure 3G). This unique propen-
sity for trabecular bone niches, similarly observed in human bone
(Figure 2), was restricted to HSCs, corroborated using over 40
individually transplanted mice (Figures 2D–2G; Figure S3), and
observed independent of varying experimental conditions that
included the level of BM engraftment, bone type (tibia, femur),
irradiation dose, or substrain of recipient mice (Figure S3).
Preferential localization of human HSCs to TBA versus LBA
available niches did not occur during initial seeding and homing
as transplantation of labeled DiI+-human HSPCs at 15 hr post-(C–E) Overall human HSC and HPC frequencies across the BM biopsy section w
stained cells (arrowheads) within total cells (DAPI+); **p < 0.01.
(F) Spatial location of human HSCs and HPCs, along with their frequencies, rela
(trabecular bone area [TBA]) and sparse cortical bone (long bone area [LBA]). Sc
(G and H) Experimental design to isolate human BMcells from trephine biopsy spe
TBA. Cortical bone regions are indicated by red asterisks.
(I) Representative fluorescence-activated cell sorting (FACS) histograms of huma
(J–L) Level of human BM cells containing primitive HSCs (J), CD49f HSC subset
(M) CFU progenitor output from freshly isolated BM from the LBA and TBA (n =
All data are represented as mean ±SEM. See also Figure S2.
Ctransplant showed no difference, whereas by 2 days the cellular
preference for TBA over LBA could be discriminated and was
stably different at 4 weeks posttransplant (Figure 3H). This indi-
cates that HSC heterogeneity both in human and mouse micro-
environment is dependent on non-cell-autonomous factors
inherent to TBA versus LBA regions and not due to immediate
homing. As illustrated in Figure 3I, to determine if in situ TBA
versus LBA location affected human HSC capacity at the func-
tional level, we examined multilineage progenitor potential, as
measured in vitro, and in vivo regeneration capacity of human
cells residing in these sites by serial BM repopulation from
primary into secondary recipients. Multilineage contribution
(lymphoid and myeloid lineages) was detected from cells har-
vested from both the TBA and LBA (Figure S3); however, an in-
crease in functional progenitor capacity (CFUs) was observed
for the human cells isolated from the TBA as compared to the
LBA of primary recipients (Figure 3J). Importantly, secondary
transplantation revealed a 3-fold increase in the level of hemato-
poietic reconstitution in mice receiving primary SRCs isolated
from the TBA (SRC-TBA) versus the LBA (SRC-LBA) (Figure 3K).
To further characterize this qualitative increase in repopulating
function, we performed limiting dilution analysis (LDA) (Bhatia
et al., 1997). Quantitatively, functional human SRC frequency
was higher from phenotypic SRCs derived from the TBA, where
more than 90% of mice receiving SRC-TBA were engrafted at
higher levels compared to those receiving SRC-LBA (Figure 3L).
Using Poisson statistics, the frequency of functional human
HSCs (SRCs) was 3.4-fold enriched in the TBA CD34+CD38
fraction (1 in 4,598) compared to the corresponding LBA fraction
(1 in 15,280) (Table S1), amounting to a 2.3-fold increase in self-
renewal capacity based on input of human HSCs in primary
recipients (Figure 3M). Thus, despite transplanting identical
numbers of the same phenotypically defined SRC population,
we observed significantly more HSCs with serial repopulating
capacity within the TBA subset as compared to the LBA. This
is conclusive evidence that the TBA harbors an increased com-
plement of human HSCs with superior repopulating and self-
renewal capacity.
The Trabecular Region Supports Molecularly Distinct
Human HSCs
To better understand the molecular nature underlying functional
differences of human HSCs in the TBA versus those found in the
LBA, we examined regulatory networks existing in HSCs versus
progenitors (HPCs) in both regions using whole-genome expres-
sion profiling (Bowman et al., 2007). To date, gene expression
profiling analysis of similar fractions of human hematopoietic
tissue has been limited to de novo isolated cells from humanere obtained by digital counting of the CD45+CD34+CD38+/ triple- or double-
tive to the endosteal surface of BM trephine biopsy specimens from enriched
ale bar, 500 mm.
cimens (G) with representative sections (H) for physical assessment of LBA and
n BM denoting the frequency of the primitive hematopoietic cell compartment.
s (K), and progenitors subsets (L) in LBA and TBA (n = 4); **p < 0.01.
2–3; *p < 0.05).
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Figure 3. Human SRCs Located in the Trabecular Niche Possess Superior Self-Renewal and Hematopoietic Regenerative Capacity
(A) Experimental design to study engrafted human hematopoietic cells location within LBA and TBA.
(B) Equivalence between histology and schematic representation of LBA and TBA in the mouse femoral bone.
(C) Representative FACS histogram of an engrafted recipient bone denoting the frequency of human chimerism (CD45) and the composition of engrafted primitive
hematopoietic cell compartment in LBA and TBA at 10 weeks posttransplantation.
(legend continued on next page)
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functionally engrafting cells residing in distinct regions of the
BM. Highly purified CD34+CD38 and CD34+CD38+ populations
generated from both human TBA-SRCs and LBA-SRCs were
isolated and compared, as illustrated in Figure 4A. HPCs derived
from either TBA or LBA were molecularly similar (Figure 4B),
whereas isolated HSCs from TBA and LBA displayed distinct
molecular phenotypes (Figure 4B). From a total of >50,000
genes, 4,228 and 1,747 genes were found to be significantly
and differentially expressed in HSC-TBA versus HSC-LBA,
respectively (fold-change R 2.5; p value < 0.05; Figure 4C;
Tables S2 and S3). To determine if the molecular differences
between TBA and LBA HSCs reflect ‘‘acquired’’ transcriptional
programs that are predetermined, and therefore dictate a prefer-
ential cell-autonomous reconstitution into the TBA or LBA or
‘‘developed’’ programs that are dynamic and responsive to
different microenvironments, we analyzed the anatomical distri-
bution of secondary HSCs using primary HSC-LBA- versus
HSC-TBA-derived cells in the SRC assay (Figure 4D). Multiline-
age analysis revealed a contribution of myeloid and lymphoid
lineages in both secondary-engrafted TBA and LBA (Figure S4A)
with a consistent enrichment for progenitor capacity from TBA-
derived cells (Figure S4B). However, independent of initial loca-
tion in the donor transplant, isolated TBA and LBA HSCs both
redistribute to TBA and LBA niches of secondary recipients (Fig-
ures 4E–4I). These results indicate that TBA versus LBA HSCs
are not fixed subpopulations of putative HSCs but a product of
in vivo niche interactions that forms the basis of differing recon-
stitution ability and HSC subclasses. Collectively, these data
reveal that BManatomical regions dictate the functional capacity
and heterogeneity of the human HSC compartment.
To determine if there were specific networks activated in the
HSCs from TBA versus LBA, we examined genes previously
associated with HSC self-renewal and reconstitution ability
(Blank et al., 2006; Chung et al., 2006; Goessling et al., 2011;
Santaguida et al., 2009; Yang et al., 2007; Zhang et al., 2006).
A subset of these genes was stringently expressed in TBA-
HSCs and includes those involved in HSC self-renewal and BM
niche retention (Figure 4G; Figure S4). Specifically, CDKN1A-
p21, JUN-B, STAT3, ID1, CDC42, PTEN, SMAD7, and PTGER2,
as well as genes involved in erythromyeloid development
(C/EBP-alpha, JAK2, and RUNX1), were upregulated in the
TBA-residing HSCs. In contrast, genes involved in HSC prolifer-
ation and survival, such as CCND1, CD44, and FGFR-1, were all
downregulated as compared to LBA HSCs (Figure 4G). Interest-(D–F) Level of BM engraftment in the LBA and TBA of total human hematopoieti
square represents a mouse, and bars represent average levels of engraftment p
(G) Frequencies of primitive CD49f HSC subsets within primitive CD34+CD38 hum
and TBA (n = 10; *p < 0.05).
(H) Homing and distribution dynamics of labeled primitive human stem cells 15 h
(I) Experimental design to study in vivo self-renewal capacity of SRCs from the L
(J) Total number of SRC-CFU per 1,000 cells produced by a CD34+CD38 subs
*p < 0.05).
(K) BM engraftment levels of secondary recipients of transplanted SRC-LBA and
(L) Limiting dilution analysis of secondary mice transplanted with freshly purified S
SRC frequencies (n = 4 doses; N = 48 mice). Horizontal bars indicate the average l
shown below as the percentage of positive mice (n = 12).
(M) Frequency of secondary human primitive hematopoietic cells generated by S
All data are represented as mean ±SEM. See also Figure S3 and Table S1.
Cingly, genes implicated in HSC mobilization and homing (CDH2,
CASR, GNAS, RAC1, RAC2, CXCR4, CD49D, and EGR1) (Can-
celas et al., 2005; Haug et al., 2008; Jansen et al., 2005; Kollet
et al., 2006) did not show significant changes (Figure S4). Aside
from genes involved in HSC biology, extended gene set enrich-
ment analysis (GSEA) revealed Notch as the most prevalent acti-
vated pathway in TBA-HSCs. These included Notch signaling
targets HES1, HES5, and MYC (Figure 4H) that have previously
been implicated in the preservation and maintenance of long-
term human HSC function (Chitteti et al., 2010; Kunisato et al.,
2003; Yu et al., 2006), as well as molecular activators of the
Notch pathway (Presenilin, Mastermind-like, and Nicastrin) (Fig-
ure 4I). Collectively, these data indicate that the TBA harbors and
generates a unique subclass of HSCs with distinct in vivo molec-
ular activation pathways where Notch activity is enriched.
Unique Osteoblasts Expressing Notch Ligands Reside
within the TBA
To better understand the cellular basis for functional and
molecular differences between human TBA- and LBA-HSC
subclasses, we expanded the depth of our analysis of human
HSPCs in xenografts shown in Figure 1 to quantitatively compare
and locate engrafting human HSCs versus HPCs among endos-
teal regions versus vascular cells in the BM of recipients. As our
ability to use multiparameter in situ analysis for both niche cell
types as well as markers for human HSCs and HPCs was limited,
we first utilized Osterix, a specific transcription factor to discrim-
inate OBs (Osx+), along with OPN+ protein to identify the endos-
teal regions in the TBA and LBA regions (Figures 5A and 5B), in
addition to CD31+ for vascular cell regions in xenografted recip-
ients. Using high content imaging (Supplemental Experimental
Procedures) to define the endosteal region or vascular cells in
the BM, the direct distal location (mm) of HSCs and HPCs could
be quantified (Figure 5D). Putative human HSCs and HPCs had
an increased preference for the endosteal regions of the TBA
versus vascular cells of the TBA, whereas in contrast, the
HSCswere equally distributed to endosteal and vascular regions
in LBA (Figure 5D). Interestingly, the HPCs have an opposite
proximity profile to HSCs for endosteal versus vascular regions
in TBA, but in the LBA, neither HPCs nor HSCs have a location
preference (Figure 5D). These results indicate that a potentially
unique niche cell type relevant for HSCs resides within the
endosteal regions that are restricted to the TBA of bone.
Given these results, and the high cellular composition of OBs
in the endosteal regions, we aimed to molecularly characterizec cells (D), primitive stem cells (E), and progenitor subsets (F). Each circle and
er cell type (n = 45; *p < 0.05, **p < 0.01, and ***p < 0.001).
an severe combined immunodeficient repopulating cells (SRCs) between LBA
r, 2 days, and 4 weeks posttransplantation (n = 4; **p < 0.01).
BA and TBA in secondary transplants.
et purified from the LBA and TBA. Values shown are mean ±SEM (n = 5–10;
SRC-TBA purified cells (n = 20; **p < 0.01).
RC-LBA and SRC-TBA subsets for the range of injected cell doses along with
evel of human chimerism for each cell dose. The frequency of engrafted mice is
RC-LBA and SRC-TBA (n = 15; **p < 0.01).
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Figure 4. Trabecular Region Supports Molecularly Distinct Human HSCs In Vivo
(A) Experimental design to isolate in vivo engrafting human hematopoietic stem cells (HSCs) and progenitors (HPCs) for whole-genome expression profile
analysis.
(B) Hierarchical cluster analysis of engrafting human HPCs and HSCs using global gene expression with significant 2-fold change (p < 0.05). Tree branch lengths
are calculated based on Pearson’s correlation coefficients. HSC-LBA, N = 2; HSC-TBA, N = 2; HPC-LBA, N = 2; and HPC-TBA, N = 2 biological replicates.
Comparison profile of engrafted human HPCs showed no statistical difference between LBA and TBA.
(C) Scatterplot of global gene expression profile between HSC-TBA and HSC-LBA with 2-fold change differences highlighted in red.
(D) Experimental design for secondary SRC transplants of primary SRC-LBA and SRC-TBA.
(legend continued on next page)
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parameter flow cytometry (LinCD45CD31Sca1CD51+)
(Anjos-Afonso and Bonnet, 2007; Lundberg et al., 2007;
Me´ndez-Ferrer et al., 2010; Raaijmakers et al., 2010; Short
et al., 2009; Walkley et al., 2008) (Figure S5). Gene expression
profiles of highly purifiedOBs from TBA and LBAwere compared
using whole genome expression profiling and extended GSEA
(Figures 5E and 5F). Strikingly, OB-TBA demonstrated increased
expression of Notch ligands Jagged-1, Jagged-2, and Delta-like
4 (Figure 5F) compared to OBs isolated from the LBA, consistent
with the aforementioned unique HSC activation profiles (Figures
4G–4I). In addition, OB-TBA possessed uniquely upregulated
Notch-specific ligand endocytic membrane trafficking partici-
pants (MIB1,MIB2, NEURL2, RNF2, RING1, and RAB14) (Hans-
son et al., 2010; Heuss et al., 2008; Itoh et al., 2003; Koo et al.,
2005; Windler and Bilder, 2010) required for recycling and pre-
sentation of Notch ligand to neighboring cells (Figure S5). Func-
tional association networks of Notch ligand maturation in OBs
from the TBA were mapped through Ingenuity Pathway Analysis
and STRING databases (Figure 5G). These data indicate that
OBs within the bone are instead not equivalent and are in fact
unique based on anatomical regions such as TBA versus LBA.
Unique Osteoblasts Allow Notch Ligand Interaction
toward Functional Human HSC Heterogeneity
Jagged-1 represents the most established regulator of Notch
signaling in hematopoiesis (Calvi et al., 2003; Kim et al., 2008;
Robert-Moreno et al., 2008; Weber et al., 2006). OBs expressing
Jagged-1 were detected in both regions of the bone, although a
3-fold greater proportion of OBs residing in the TBA expressed
Jagged-1 (Figure 5H). As parental mesenchymal stem cells
(MSCs) (Me´ndez-Ferrer et al., 2010; Omatsu et al., 2010; Sac-
chetti et al., 2007) give rise to OB progeny, MSCs coexpressing
Jagged-1 were similarly enriched in the TBA, whereas vascular
niche cells (endothelial cells [ECs]) coexpressing Jagged-1
were nearly undetectable in both TBA and LBA (Figure 5I). This
further supports the notion that observed differences of TBA-
HSCs are based not on numbers of OBs in the TBA but on
the type of OBs indigenous to the TBA. We next used in situ
quadruple parameter staining of xenografted recipient mouse
BM to allow physical validation of these niche-to-human HSC
interactions. Human HSCs were associated with a subset of
OPN+ Osx+ osteoblasts (Figure S6) that specifically expressed
Jagged-1 in the TBA versus the LBA of recipientmice (Figure 6A).
Complete quantitative analysis using high-resolution imaging of
15 bone samples taken from engrafted mice indicated that
human HSCs preferentially interacted with OB niche cells ex-
pressing Jagged-1 in the TBA (Figure 6C).
We hypothesized that unique BM niche regions, with specific
Notch signaling, could inform our understanding of human HSC(E and F) Level of secondary human HSC and HPC engraftment in LBA and TBA
shown are mean ±SEM (n = 15; **p < 0.01).
(G) Overview of main genes differentially expressed in both SRC-LBA and SRC-
(H) Expression data were analyzed for the molecular signature of Notch signaling
heat map show significant upregulation of Notch signaling activation in SRC-TB
(I) Quantitative PCR validation of selected Notch pathway components in SRC-L
(n = 5; *p < 0.05, **p < 0.01).
All data are represented as mean ±SEM. See also Figure S4 and Tables S2 and
Cheterogeneity. Using de novo isolated human HSCs, we tested if
varying degrees of Notch ligand-binding affinity would allow
enrichment of human HSCs (Figure 6D). The specificity of the
Notch ligand interaction was verified using a Jagged-1-conju-
gated FLAG-tagged competitive binding assay (Karanu et al.,
2000; Karanu et al., 2001) (Figure S6). Based on Notch ligand
binding affinities, primitive (lineage-depleted) human hematopoi-
etic cells were found to be heterogeneous with respect to
Jagged-1 binding and allowed for the isolation of Jag-1binder
and Jag-1nonbinder fractions (Figure 6E). Progenitor (CFU) capac-
ity of human Jag-1binder hematopoietic cells was found to be
higher than Jag-1nonbinder cells (Figure 6F; Table S4). To assess
the in vivo hematopoietic regenerative potential, Jag-1binder
and Jag-1nonbinder fractions were transplanted into recipient
mice for quantitative LDA analysis. The number of reconstitut-
ing cells was significantly higher in the Jag-1binder fraction com-
pared to Jag-1nonbinder cells (Figure 6G). Up to 80% of mice
receiving 5,000–10,000 Jag-1binder cells were engrafted with
multilineage hematopoiesis (Figure S6), while no human HSC
activity was measurable at this dose in mice transplanted with
Jag-1nonbinder cells (Figure 6G). In fact, an escalating dose of
30,000 Jag-1nonbinder cells was required to detect any hemato-
poietic regenerative capacity (SRC content). Using Poisson
statistics (Table S5), the frequency of human SRCs was 7.5-
fold enriched in the Jag-1binder fraction (1 in 5,253) compared
to the Jag-1nonbinder fraction (1 in 39,486). Interestingly, the
enrichment of human HSCs achieved using Jag-1binder cells
delivered intravenously into the circulation was similar to that re-
ported using the LinCD34+CD38marker combination for HSC
isolation followed by delivery to the BM niche by direct intrafe-
moral injection (Mazurier et al., 2003; McKenzie et al., 2005).
To examine the effects of Notch signaling in vivo, we adminis-
tered gamma-secretase inhibitors (DAPT) to engrafted recipient
mice (Medyouf et al., 2010) as illustrated in Figure 6H. The
specificity of the inhibitory effect of DAPT treatment on Notch
signaling was assessed by measurement of the activated
Notch-receptor intracellular domain (NICD) (Figures 6I and 6J).
Upon DAPT treatment in vivo, total engraftment levels and
HSC and progenitor number were not altered in response to
Notch inhibition in the LBA (Figures 6K and 6L), suggesting this
region is not sensitive to Notch regulation. In contrast, total level
of engraftment was decreased, as well as a reduction in HSC
populations in the TBA in response to DAPT treatment (Fig-
ure 6L). In addition, the progenitor fraction exclusive to the
TBA was increased in response to Notch inhibition (Figure 6L),
suggesting that disruption of Notch signals uniquely induces a
loss in HSCs residing in the TBA, potentially inducing dif-
ferentiation into progenitors and a collective overall reduction
in human engraftment in a region specific manner. More impor-
tantly, inhibition of Notch signaling had a functional impact onof transplanted recipients with primary SRC-LBA (E) and SRC-TBA (F). Values
TBA.
using gene set enrichment analysis (GSEA). Enrichment plot and the resulting
A compared to SRC-LBA.
BA and SRC-TBA relative to de novo purified CD34+CD38 cells (arrowhead)
S3.
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Figure 5. The Trabecular Niche Supports Molecularly Distinct Human HSCs In Vivo
(A and B) Distribution of engrafting human CD34+ cells (white arrows) between LBA and TBA associated with either OPN+ Osx+ cells to define endosteal
regions (yellow arrowheads) or CD31+ vascular cells (n = 10 sections) to define vascular niches as detailed in the Supplemental Experimental Procedures. Scale
bars, 10–50 mm.
(C) Representative total distribution of individually detected HSCs (CD34+CD38CD45+) and HPCs (CD34+CD38+CD45+) within representative whole-bone
sections.
(D) Proximity distribution of human HSCs (n = 673) and HPCs (n = 2,060) to either endosteal or vascular regions in both TBA and LBA (n = 2–3 sections); the red
dotted line marks the limit of the endosteum surface for endosteal distance only (15 mm).
(E) Hierarchical cluster analysis of purified mouse osteoblasts (OBs) using global gene expression with significant 1.5-fold change (p < 0.01). Tree branch lengths
are calculated based on Pearson’s correlation coefficients. OB-LBA, N = 2 and OB-TBA, N = 2 biological replicates.
(F) Enrichment plot and resulting heat map by GSEA show significant upregulation of Notch ligand maturation in OB-TBA compared to OB-LBA.
(G) Confidence view of relevant functional association network generated using Ingenuity Pathway Analysis and STRING databases; stronger associations are
represented by thicker lines and indicated by confidence scores.
(H) Representative FACS histogram of recipient osteoblasts expressing Jagged-1.
(I) Frequencies of recipient putative osteoblasts, mesenchymal stem cells (MSCs) and endothelial cells (ECs) expressing Jagged-1 in LBA and TBA (n = 10;
**p < 0.01).
All data are represented as mean ±SEM. See also Figure S5.
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(Figure 6M; Figure S6). These observations support the notion
that HSC function is more likely non-cell-autonomous but is
heavily regulated by specific interaction with different special-
ized BM niches, as exemplified using Notch disruption unique
to the TBA HSCs.
DISCUSSION
Our results reveal that direct characterization of indigenous
human HSCs within the bone of humans uncovers unique inter-
actions and location propensities that control HSC capacity
in vivo. Both the anatomical and cellular composition of the
bone was shown to be functionally heterogeneous in humans
as well as xenografted models where rare human HSCs were
located. Consideration of both larger anatomical features of
bone and detailed cellular niche in the BM space allowed for
the identification of a subclass of human HSCs (TBA-HSCs).
Human TBA-HSCs have superior regenerative and self-renewal
capacities compared to those in the LBA and reside close to
unique endosteal regions and OBs that differ from the OB
composition of LBA. Phenotypically identical human HSCs
found in the TBA were also molecularly distinct to those residing
in the LBA, whereas the expression profile of human blood pro-
genitors were identical in both bone locations. These results
demonstrate that this niche-to-hematopoietic cell interaction is
unique to the HSC compartment.
Beyond all known markers predicted from mouse BM niche
studies, OBs in the TBA and LBA were not equivalent, indi-
cating that the bone is not a continuum of cellular elements
but is functionally divisible into discrete anatomical compart-
ments, each possessing unique microenvironmental cell types.
Collectively, these observations indicate a level of previously
unappreciated complexity within the BM anatomy that defines
and ultimately governs HSC behavior in vivo. Our results were
based on unbiased in situ analysis; this biology of human
HSCs could not have been elucidated using classical prospec-
tive isolation-transplantation studies. One such example of
biological network of cell-to-cell interactive signals identified
in this study that was unique to TBA involved the Notch axis.
These in vivo findings are consistent with human studies that
have shown ex vivo cultured cells treated with Notch ligand
have increased hematopoietic capacity upon transplantation
in human patients (Delaney et al., 2010). In this previous study,
Notch ligand addition augmented HSC function, but was not
essential, as untreated cells also retained regenerative capac-
ity. Our results suggest Notch ligand interactions manifest
beneficial effects in vivo upon transplantation, where anchorage
to and/or signal from unique niche cells such as TBA-OBs
expressing Notch ligand assist in increasing individual HSC
capacity. However, the Notch pathway via OBs are likely only
one means of augmenting HSCs, and even this effect could
be mediated by non-cell-autonomous roles of other niche com-
ponents and pathways to impact HSC biology. As the in vivo
niche location of cultured versus uncultured human HSCs after
transplantation has not been determined or compared, different
preparations of human HSC or the manipulation of the recipient
BM to increase individual HSC regenerative capacity should be
explored.CLike all stem cells, mammalian HSCs are defined by their
developmental potential. HSCs are viewed as individual cellular
entities but are dependent on BM to function. Our current study
shows that the BM is heterogeneous at two levels: anatomically
and cellularly. We demonstrate that these combined properties
of BM architecture ultimately define HSC behavior, independent
of phenotypes assigned to HSCs from previous prospective
isolation-transplantation testing experiments. Our findings intro-
duce a unique paradigm to categorize human HSCs, where the
BM defines all observable characteristics of HSCs operating
in vivo. Previous (classical) studies using prospective isolation
to define putative HSCs prior to transplantation could not un-
cover these BM regulatory properties and associated sub-
classes of human HSCs functionally and molecularly classified
here. We suggest that cell-surface markers, genotype, or molec-
ular signatures prior to transplantation cannot define HSCs, as
HSC are subjected to in vivo phenotypic variation where the
BM anatomy and cellular architecture is the governing variable
(see Graphical Abstract). We propose an ‘‘extended phenotype’’
to collectively define human HSCs function that incorporates
both the HSC as a cellular entity defined by cell-surface markers,
plus the functional properties of BM niche cells that would
include BM architecture, to better describe the properties that
operationally define human HSCs.
EXPERIMENTAL PROCEDURES
Human BM Samples
Trephine BM biopsy specimens measuring between 1.5 and 2 cm were
obtained from the posterior ileac crests of lymphoma patients undergoing
staging of their disease at time of diagnosis (London Health Sciences Centre,
Ontario, Canada) under the approval of the research ethics office of Western
University (Ethics File #103879). Only samples from patients without BM
involvement were used in this study. Results from their clinical assessment,
including disease/stage, morphologic evaluation of marrow aspirate and
biopsy specimen, flow cytometry, and cytogenetics, are summarized in Table
S6. Immediately after collection, the distal portion of the biopsy core was
tagged with color dye to discriminate the proximal portion of the biopsy core
(subcortical; more trabecular) from the distal portion (more central; less
trabecular) and then measured and surgically separated, with histological
sections being obtained from each part to assess and confirm anatomical
core orientation.
Mice
NOD/Prkdcscid (NOD/SCID) (Larochelle et al., 1996) and b2 microglobulin
knockout (NOD/SCID/B2null) (Christianson et al., 1997) mice were bred and
maintained in the Stem Cell and Cancer Research Institute (SCC-RI) animal
barrier facility at McMaster University. All animal procedures received the
approval of the animal ethics board at McMaster University. See the Supple-
mental Experimental Procedures for a description of transplantation and in vivo
treatment procedures.
Purification and Phenotyping of Cells
All donor samples were obtained with the approval of local human subject
research ethics boards at McMaster University. Human umbilical cord blood
mononuclear cells were isolated as described previously (Bhatia et al.,
1997). For CD49f fractions, engrafted suspension cells were stained as
described previously (Notta et al., 2011). See the Supplemental Experimental
Procedures for additional details.
In Situ Imaging Analysis
Images of human BM sections were acquired at 203 with an Operetta HCS
Reader (Perkin Elmer) by means of epifluorescence illumination and standard
filter sets. Image processing and analysis was performed using custom scriptsell Stem Cell 13, 175–189, August 1, 2013 ª2013 Elsevier Inc. 185
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Characterization of Bone Marrow Niche in Humansin Acapella software (version 2.7, Perkin Elmer) and MATLAB (version 2012a,
Mathworks). See the Supplemental Experimental Procedures for additional
details.
In Vitro Assays
Purified LinCD34+Notch+ and LinCD34+Notch cell populations were
cultured in serum-free medium containing hematopoietic cytokines using
fibronectin-coated plates (n = 10). Human clonogenic progenitor assays
were done by plating freshly isolated or cultured cells in semisolid methylcel-
lulose medium (Methocult H4230, Stem Cell Technologies). See the Supple-
mental Experimental Procedures for specific procedures.
Molecular Analysis
Freshly isolated cells were sorted based on surface marker expression and
total RNA was extracted and amplified as shown previously (Wang et al.,
2004) from each purified population. Total cellular RNA was isolated using
the RNeasy Plus Mini kit according to the manufacturer’s instructions
(QIAGEN) and complementary DNA was synthesized using qScript SuperMix
(Quanta Biosciences). See the Supplemental Experimental Procedures for
specific procedures.
Statistical Analysis
Statistical analysis was performed by using two-tailed t test comparison, Kol-
mogorov-Smirnov test, and two-way ANOVAwith GraphPad Prism (GraphPad
Software). Values were compared as means ±SEM, and p < 0.05 was consid-
ered statistically significant and is indicated by asterisks in the figures.
ACCESSION NUMBERS
The microarray data have been deposited in Gene Expression Omnibus of the
National Center for Biotechnical Information under the accession number
GSE47936.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes Supplemental Experimental
Procedures, six figures, and six tables and can be found with this article online
at http://dx.doi.org/10.1016/j.stem.2013.06.015.
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